• Alzamend Neuro is trading 5.2% down today at $1.09.
  • The company recently reported a net loss of $2.7 million, with an earnings per share (EPS) of $(1.28), significantly worse than the estimated EPS of $(0.69) (analyst reports as of July 7, 2026).
  • Analysts also highlight ongoing risks including liquidity challenges and the potential failure of drug candidates.